BCX-34 update

BCRX reported that BCX-34 was well tolerated, with no significant toxicity, in an open label Phase I study.

Three patients with stage IB and IIB disease were administered 36-42 mg of iv drug, followed a week later by the same dose orally, followed three weeks later by a five-day consecutive oral dosing regimen. ...